Rubicon Research IPO Details: Launch Date, Share Price, Size & Review

 

The Business Profile of the Rubicon Research Limited

Rubicon Research Limited has been fastest growing Indian pharmaceuticals Formulations Company that focuses on innovation and research, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly the United States. In Fiscal 2024, among its 55 commercialized products, the company held a market share of more than 25% by volume for seven products.

The company’s Commercialized Products portfolio primarily consists of products in the analgesics/pain management therapy area. As of February 2024, there are an estimated 129 million individuals in the United States affected by at least one major chronic disease. Chronic therapies are long-term treatments designed to manage ongoing health conditions, often requiring continuous medication over extended periods of time.

The company has two US FDA inspected R&D facilities and two manufacturing facilities in India with multiple accreditations.

The Main Objectives to Launch the Rubicon Research Limited IPO

As per the draft red hearing prospects, Rubicon Research Limited issue consists of both fresh issue and offer for sale by the promoter of the company. One of the main objectives of the company is to list on the bourses and also give the option to sell some of the stakes in the company.

The offer for sale (OFS) consists of up to [●] equity shares aggregating up to ₹ 5,850 million. Nothing from those proceeds of OFS will be allotted to company.

Rubicon Research issue has fresh issue aggregating up to ₹ 5,000 million. According to the document, Rs. 3,100 milion will be utilized for repayment of certain borrowings over next two years and rest of the funds will be utilized for strategic acquisitions and General corporate purposes

Should You Subscribe to Rubicon Research Limited IPO or Not

While investing or subscribing to any IPO, consider the investment rationales related to the company. Hence, here you can find out the strength of the company that will be its growth factors. And also check the risk factors that can affect the growth and operational efficiency of the company.

Competitive Strengths of the Company:

Fastest growing Indian pharmaceutical Co.: Companies revenue grew at a CAGR of 62.5% between FY22 to FY24, making us the fastest-growing Indian company among peers. Despite competition the company has managed to grown its market share in several products. From its commercialized products, the company hold market share of over 25% for seven products in the US market. In Fiscal 2024, we ranked among the top 10 Indian companies in terms of total ANDA approvals.

Comments

Popular posts from this blog

IPO allotment for retail: how are shares allotted for the retail category

How to Deploy Strategy in Algo Test with Moneysukh Trade Radar

How to Decide Best Entry & Exit Points in Intraday Trading?